ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1241

Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Abstract Number: 0741

Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors
Abstract Number: 0464

Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Abstract Number: 1395

Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Abstract Number: 2146

After JAK Inhibitor Failure, “Switching” or “Cycling”?
Abstract Number: 2272

Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States
Abstract Number: 2457

Ageism in Rheumatology: The Health Care Professional’s Perspective
Abstract Number: 1242

Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1810

Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Abstract Number: 2491

Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Abstract Number: 1169

All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
Abstract Number: 0069

All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome
Abstract Number: 0363

Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
Abstract Number: 0697

Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Abstract Number: 0018

Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].